BRANMOOR
THURSDAY · 14 MAY 2026

Nucala

FDA Adverse Event Reporting System · 2025 window

Rank #94 by volume 6,744 reports in 2025

2025 report counts

Total adverse-event reports
6,744
Classified as serious
2,321
Reports with fatal outcome
881
Fatality share of serious reports
38.0%
Rank in window (by total report volume)
#94 of 500

Top reported reactions (serious-only)

The 10 most-reported reactions among serious-classified FAERS reports for this drug in 2025. MedDRA preferred terms.

Reaction (MedDRA PT)2025 reports
Off Label Use 479
Dyspnoea 471
Wheezing 462
Pain 429
Condition Aggravated 420
Asthma 410
Maternal Exposure During Pregnancy 389
Drug Ineffective 388
Gastrooesophageal Reflux Disease 375
Product Use In Unapproved Indication 359

Important caveats

FAERS report counts are a reporting signal, not a clinical assertion of causation. Higher report volumes correlate with: larger treated populations, established manufacturer pharmacovigilance infrastructure, sicker patient populations (specialty biologics for serious disease will always attract more reports than common over-the-counter agents), and reporter familiarity with the reporting workflow.

The paid FAERS Signal Surveillance product adds the disproportionality analysis (Information Component, Empirical Bayes Geometric Mean, Proportional Reporting Ratio) that normalizes these confounders and surfaces emerging signal against the FAERS baseline. See the product page.

For the canonical FDA record, see the FAERS Public Dashboard.

‹ All drugs